Toru Aoyama
Yokohama City University
CancerInternal medicineSurgeryOncologyRetrospective cohort studyPathologicalChemotherapyAdjuvantEsophageal cancerSurgical oncologyPancreatic cancerGastrectomyLymph nodeIn patientAdjuvant chemotherapyMultivariate analysisRisk factorColorectal cancerMedicineGastroenterology
344Publications
26H-index
1,689Citations
Publications 356
Newest
#1Keisuke KazamaH-Index: 5
#2Manabu ShiozawaH-Index: 26
Last. Yasushi Rino (YCU: Yokohama City University)H-Index: 33
view all 12 authors...
Purpose null The efficacy of fluorouracil + oxaliplatin + irinotecan with bevacizumab (FOLFOXIRI + BV) has been verified for metastatic colorectal cancer (mCRC). In clinical practice, the original (O-FOLFOXIRI + BV) and modified dose settings (M-FOLFOXIRI + BV) are adopted for Asian patients. We aimed to compare the real-world efficacy and safety of these two regimens. null Methods null This retrospective cohort study reviewed clinical data of all consecutive mCRC patients treated with FOLFOXIRI...
Source
#1Yosuke Atsumi (YCU: Yokohama City University)H-Index: 4
#2Shinnosuke Kawahara (YCU: Yokohama City University)H-Index: 1
Last. Hiroshi Tamagawa (YCU: Yokohama City University)H-Index: 11
view all 13 authors...
AIM Recent studies have reported that the albumin-to-globulin ratio (AGR) may be a useful inflammatory-nutritional biomarker to predict postoperative complications and poor prognosis in various types of patients with cancer. However, its prognostic value in patients with esophageal cancer is still unclear. We aimed to examine the utility of the AGR for predicting the short- and long-term outcomes in patients with esophageal cancer who underwent curative resection. PATIENTS AND METHODS This was a...
Source
#1Toru Aoyama (YCU: Yokohama City University)H-Index: 26
#2Masato Nakazono (YCU: Yokohama City University)H-Index: 4
Last. Kazuki Kano (YCU: Yokohama City University)H-Index: 5
view all 18 authors...
BACKGROUND/AIM The number of patients who have cardiovascular-morbidities and use antiplatelet and/or anticoagulation therapy is rapidly growing worldwide. The present study evaluated the safety and feasibility of gastrectomy for gastric cancer in patients who received antiplatelet and/or anticoagulation therapy in the perioperative period. PATIENTS AND METHODS Cases were selected from the medical records of consecutive patients who were diagnosed with gastric cancer and underwent complete resec...
Source
#1Hiroshi Tamagawa (YCU: Yokohama City University)H-Index: 11
#2Masakatsu Numata (YCU: Yokohama City University)H-Index: 5
Last. Takashi OhshimaH-Index: 4
view all 16 authors...
Background null Resection of the primary lesion with radical lymph node dissection is the most promising treatment avenue for patients with cancer. On the other hand, these procedures often induce excessive intraoperative blood loss (IBL) and require perioperative blood transfusion. The influence of IBL on the long-term postoperative outcomes of patients with digestive cancer is controversial. We investigated the impact of IBL on survival and recurrence after curative surgery in patients with co...
Source
#1Toru Aoyama (YCU: Yokohama City University)H-Index: 26
#2Masato Nakazono (YCU: Yokohama City University)H-Index: 4
Last. Hideaki Suematsu (YCU: Yokohama City University)H-Index: 2
view all 18 authors...
BACKGROUND We investigated the impact of the pre-surgical C-reactive protein-to-albumin ratio (CAR) on survival and recurrence after curative treatment for gastric cancer. PATIENTS AND METHODS This study included 481 patients who underwent curative treatment for gastric cancer between 2013 and 2017. The risk factors for overall (OS) and recurrence-free (RFS) survival were identified. RESULTS A CAR of 0.05 was regarded as the optimal critical point of classification considering the 3- and 5-year ...
Source
#1Toru AoyamaH-Index: 26
#2Masato NakazonoH-Index: 4
view all 16 authors...
Source
#1Masakatsu Numata (YCU: Yokohama City University)H-Index: 5
#2Manabu ShiozawaH-Index: 26
Last. Yasushi Rino (YCU: Yokohama City University)H-Index: 33
view all 22 authors...
BACKGROUND AND OBJECTIVES Contrary to the Japanese guidelines recommendations regarding lateral lymph node dissection (LatLND) for rectal cancer, its omission is common in clinical practice without reliable omission criteria. Negative pathological mesorectal lymph node metastasis (MesLNM) is reportedly highly correlated with negative pathological lateral lymph node metastasis (p-LatLNM); however, this cannot be used as a criterion because pathological features are revealed postoperatively. Herei...
Source
#1Yosuke Atsumi (YCU: Yokohama City University)H-Index: 4
#2Masakatsu Numata (YCU: Yokohama City University)H-Index: 5
Last. Sumito Sato (YCU: Yokohama City University)
view all 19 authors...
Aim null D3 lymph node dissection (LND) for stage II and III colon cancer has been shown to improve prognosis, however, it generally increases surgical stress. Studies have reported that the C-reactive protein/albumin ratio (CAR) may be a useful inflammatory-nutritional biomarker to predict postoperative complications and poor prognosis for with various types of cancer. Our purposes were to assess the short- and long-term outcomes of D3 LND in patients with a high preoperative CAR (≥ 0.04). null...
Source
#1Yasushi Rino (YCU: Yokohama City University)H-Index: 33
#2Norio Yukawa (YCU: Yokohama City University)H-Index: 19
Last. Tsutomu Sato (YCU: Yokohama City University)H-Index: 22
view all 14 authors...
Source
#1Kenki Segami (YCU: Yokohama City University)H-Index: 3
#2Toru Aoyama (YCU: Yokohama City University)H-Index: 26
Last. Yukio MaezawaH-Index: 7
view all 0 authors...
Background/aim null Cancer stem cells (CSCs) are reported to associated with cancer metastasis, relapse, and chemoresistance. This study examined the clinical significance of the expression of two CSC markers, the transporter associated with antigen processing 1 (TAP1) and the Delta-like 4 (DLL4) protein, in patients with locally advanced GC. null Patients and methods null This study was performed using samples obtained from 413 pathological stage II/III GC patients after curative gastrectomy. W...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.